Long-term efficacy and renal safety of SGLT2 inhibitors in patients with heart failure and advanced chronic kidney disease (stage 4): a propensity score-matched retrospective cohort study - Takeaways - MDSpire

Long-term efficacy and renal safety of SGLT2 inhibitors in patients with heart failure and advanced chronic kidney disease (stage 4): a propensity score-matched retrospective cohort study

  • By

  • Weihua Peng

  • Xiaoke Shang

  • Changdong Zhang

  • Mei Liu

  • June 17, 2026

  • 0 min

Share

  • 1

    SGLT2 inhibitors (SGLT2i) show a 38% relative risk reduction in heart failure hospitalization or cardiovascular death in patients with advanced CKD.

  • 2

    The study included 320 heart failure patients with a median eGFR of 22.4 mL/min/1.73 m2, comparing SGLT2i treatment to standard care.

  • 3

    The incidence of major adverse kidney events was similar between SGLT2i and control groups, indicating renal safety in advanced CKD patients.

  • 4

    SGLT2i therapy resulted in a shallower annualized eGFR decline compared to standard care, suggesting better long-term renal function preservation.

  • 5

    Findings support the use of SGLT2i in heart failure patients with severe renal impairment, challenging the notion of avoiding this therapy.

Original Source(s)

Related Content